- Home
- CLLS vs SCD Comparison
CLLS vs SCD Comparison
Compare CLLS & SCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SCD
- Stock Information
- Founded
- CLLS 1999
- SCD 2003
- Country
- CLLS France
- SCD United States
- Employees
- CLLS N/A
- SCD N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SCD Trusts Except Educational Religious and Charitable
- Sector
- CLLS Health Care
- SCD Finance
- Exchange
- CLLS Nasdaq
- SCD Nasdaq
- Market Cap
- CLLS 240.2M
- SCD 259.3M
- IPO Year
- CLLS 2007
- SCD N/A
- Fundamental
- Price
- CLLS $1.99
- SCD $17.33
- Analyst Decision
- CLLS Buy
- SCD
- Analyst Count
- CLLS 2
- SCD 0
- Target Price
- CLLS $8.00
- SCD N/A
- AVG Volume (30 Days)
- CLLS 23.1K
- SCD 62.6K
- Earning Date
- CLLS 11-04-2024
- SCD 01-01-0001
- Dividend Yield
- CLLS N/A
- SCD 9.63%
- EPS Growth
- CLLS N/A
- SCD N/A
- EPS
- CLLS N/A
- SCD N/A
- Revenue
- CLLS $19,635,000.00
- SCD N/A
- Revenue This Year
- CLLS $271.02
- SCD N/A
- Revenue Next Year
- CLLS $33.48
- SCD N/A
- P/E Ratio
- CLLS N/A
- SCD N/A
- Revenue Growth
- CLLS N/A
- SCD N/A
- 52 Week Low
- CLLS $0.96
- SCD $11.33
- 52 Week High
- CLLS $3.77
- SCD $15.87
- Technical
- Relative Strength Index (RSI)
- CLLS 38.05
- SCD 54.79
- Support Level
- CLLS $1.95
- SCD $17.36
- Resistance Level
- CLLS $2.06
- SCD $17.91
- Average True Range (ATR)
- CLLS 0.10
- SCD 0.39
- MACD
- CLLS -0.02
- SCD -0.06
- Stochastic Oscillator
- CLLS 20.93
- SCD 32.75
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships.